AstraZeneca PLC
AZN
$89.10
$0.490.55%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 11.99% | 11.74% | 7.17% | 23.84% | 18.04% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.99% | 11.74% | 7.17% | 23.84% | 18.04% |
| Cost of Revenue | -7.11% | 16.86% | 0.68% | 35.14% | 47.06% |
| Gross Profit | 17.60% | 10.70% | 8.55% | 21.48% | 11.57% |
| SG&A Expenses | -3.18% | -1.52% | -1.21% | 36.24% | 7.28% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -256.00% | -20.00% | -70.15% | 42.86% | 64.29% |
| Total Operating Expenses | -0.32% | 7.63% | 2.38% | 32.53% | 20.14% |
| Operating Income | 78.96% | 26.98% | 21.86% | 1.26% | 7.78% |
| Income Before Tax | 77.46% | 30.45% | 21.50% | 85.73% | 10.65% |
| Income Tax Expenses | 79.49% | 44.78% | -22.42% | 367.74% | 44.16% |
| Earnings from Continuing Operations | 76.90% | 26.97% | 33.99% | 56.41% | 3.99% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 50.00% | 300.00% | -400.00% | -100.00% | 0.00% |
| Net Income | 77.26% | 27.14% | 33.82% | 56.25% | 4.00% |
| EBIT | 78.96% | 26.98% | 21.86% | 1.26% | 7.78% |
| EBITDA | 35.56% | 21.14% | 16.25% | -0.90% | 23.36% |
| EPS Basic | 77.15% | 27.06% | 33.74% | 56.13% | 3.93% |
| Normalized Basic EPS | 88.01% | 29.72% | 25.56% | 0.57% | 10.62% |
| EPS Diluted | 78.02% | 27.63% | 33.57% | 56.70% | 3.41% |
| Normalized Diluted EPS | 88.23% | 29.88% | 25.56% | 0.57% | 10.56% |
| Average Basic Shares Outstanding | 0.06% | 0.06% | 0.06% | 0.06% | 0.06% |
| Average Diluted Shares Outstanding | -0.06% | -0.06% | 0.06% | 0.06% | 0.13% |
| Dividend Per Share | -- | 3.00% | -- | 6.60% | -- |
| Payout Ratio | -0.42% | -0.54% | -0.18% | -0.04% | 0.07% |